Last reviewed · How we verify
Omega 3
Omega 3, marketed by Assiut University, is positioned in the treatment of severe hypertriglyceridemia. The key composition patent expires in 2028, providing a period of exclusivity that supports market stability. The primary risk is the lack of reported revenue and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | Omega 3 |
|---|---|
| Also known as | fish oil, Fish oil, omega-3 supplementation capsules, omega 3 fatty acid, docosahexaenoic acid |
| Sponsor | Assiut University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Severe Hypertriglyceridemia
Common side effects
Drug interactions
- anticoagulants or other drugs affecting coagulation (e.g., anti-platelet agents)
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction (PHASE2)
- Pre-Surgical Immunonutrition's Effect on Colorectal Surgery (NA)
- Omega-3 Supplementation vs Demodex vs Eyelid Cleanser for Pediatric Chalazia (PHASE2)
- FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM) (PHASE2)
- Heart & Health Study (NA)
- NMDA Enhancement Combined With Omega-3 for Early Dementia (PHASE2)
- A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |